N&O 100
Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
ANTHERA PHARMA (NQ: ANTH)
0.5800 USD  -0.0280 (-4.61%)
Official Closing Price  /  Updated: 8:10 PM EDT, May 20, 2013  /  Add to My Watchlist      
View: Quote News
Press releases about ANTHERA PHARMA
 
< Previous 1 2 3 Next >
Anthera Pharmaceuticals Reports 2013 First Quarter Financial Results
May 13, 2013
from PR Newswire
Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study
May 07, 2013
Two oral presentations at EULAR will review the impact of blisibimod on renal biomarkers and improved outcomes in systemic lupus erythematosus (SLE) patients Read More
from PR Newswire
Anthera Announces First Quarter 2013 Financial Report and Conference Call
May 03, 2013
from PR Newswire
Amarin, Pharmacyclics, Anthera Pharma, Star Scientific, and Impax Laboratories Under StockCall's Microscope
April 16, 2013
from PR Newswire
Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing Facility
April 05, 2013
Debt Related Expense to Decrease by Over $600K per Month through 2014 Read More
from PR Newswire
Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
March 27, 2013
from PR Newswire
Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
March 26, 2013
from PR Newswire
Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
March 22, 2013
from PR Newswire
StockCall Pre-Market Review on Anthera Pharma, Impax Laboratories, Star Scientific, and Cubist Pharma
March 18, 2013
from PR Newswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Anthera Pharmaceuticals, Inc. in Connection with Executive Comp
February 13, 2013
from Business Wire News Releases
Faruqi & Faruqi, LLP is Investigating Anthera Pharmaceuticals Incorporated on Behalf of its Shareholders - ANTH
February 13, 2013
from PR Newswire
Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
February 07, 2013
from PR Newswire
Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil
February 05, 2013
from PR Newswire
Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
January 30, 2013
from PR Newswire
Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
January 25, 2013
from PR Newswire
Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
January 24, 2013
from PR Newswire
The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Anthera Pharmaceuticals, Inc. in Connection with Executive Compens
January 23, 2013
from PR Newswire
Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
November 28, 2012
from PR Newswire
Free Research Reports on ACAD, ANTH, BPAX, VHC Issued by the Bedford Report
November 26, 2012
Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT Read More
from Marketwired News Releases
Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
November 20, 2012
from PR Newswire
Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
November 13, 2012
from PR Newswire
Biotech Industry Experiencing More FDA New Drug Approvals in 2012
November 13, 2012
Five Star Equities Provides Stock Research on Anthera Pharmaceuticals and SciClone Pharmaceuticals Read More
from Marketwired News Releases
Free Research Reports on ALU, ANTH, MYGN and WPRT Issued by the Bedford Report
November 07, 2012
Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT Read More
from Marketwired News Releases
Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
November 01, 2012
from PR Newswire
Anthera Pharmaceuticals Reports 2012 Third Quarter Financial Results And Provides Clinical Progress Update
October 24, 2012
from PR Newswire
Anthera Announces Third Quarter 2012 Financial Report and Conference Call
October 18, 2012
from PR Newswire
Faster FDA Review Process a Contributing Factor to Biotech Industry's Rise in 2012
September 20, 2012
The Paragon Report Provides Stock Research on Anthera Pharmaceuticals and Catalyst Pharmaceutical Read More
from Marketwired News Releases
Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
September 17, 2012
from PR Newswire
Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
August 07, 2012
from PR Newswire
Anthera to Report Second Quarter 2012 Financial Results
August 01, 2012
from PR Newswire
< Previous 1 2 3 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here